Published in Medicine (Baltimore) on June 01, 2016
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum (1980) 21.86
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest (2007) 5.19
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) (2002) 2.86
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis (2007) 2.60
Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum (2006) 2.04
Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol (2015) 2.02
Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis (2013) 1.90
Assessment of disease severity and prognosis. Clin Exp Rheumatol (2003) 1.86
Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol (2006) 1.85
Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol (2006) 1.73
Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol (2008) 1.37
Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum (2011) 1.35
The immunobiology of systemic sclerosis. Semin Arthritis Rheum (2008) 1.22
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum (2009) 1.18
A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum (2003) 1.14
Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol (1998) 1.08
Autoantibodies in systemic sclerosis. Autoimmun Rev (2012) 1.05
Systemic sclerosis-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 1.03
Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis (2010) 1.02
Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 0.94
Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) (2012) 0.94
Primary pulmonary hypertension: an overview of epidemiology and pathogenesis. Cleve Clin J Med (2003) 0.93
The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol (2005) 0.91
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther (2012) 0.90
Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev (2010) 0.89
Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev (2009) 0.89
Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol (2012) 0.87
Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol (1989) 0.86
Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken) (2014) 0.85
Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. Rheumatology (Oxford) (2015) 0.85
Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor. Scand J Rheumatol (2011) 0.82
Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta (2011) 0.81
Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol (2010) 0.81
The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). Clin Immunol (2010) 0.79
Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum (2014) 0.78
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis. Arthritis Res Ther (2013) 0.77
Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care Res (Hoboken) (2013) 0.77
Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis. PLoS One (2013) 0.76
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin. Autoimmun Rev (2015) 0.76
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) (2002) 2.86
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol (2002) 1.97
Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev (2008) 1.91
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Inappropriate exercise-induced increase in pulmonary artery pressure in patients with systemic sclerosis. Heart (2010) 1.61
Extra-skeletal effects of bisphosphonates. Joint Bone Spine (2006) 1.59
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford) (2010) 1.58
Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol (2003) 1.55
Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension. Arthritis Rheum (2013) 1.51
Osteoblast physiology in normal and pathological conditions. Cell Tissue Res (2010) 1.49
Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol (2003) 1.36
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol (2013) 1.31
Foot involvement in systemic sclerosis: a longitudinal study of 100 patients. Semin Arthritis Rheum (2002) 1.27
Vitamin D and the immune system. J Rheumatol (2010) 1.22
Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis (2012) 1.21
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum (2011) 1.15
Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity. Arthritis Rheum (2012) 1.06
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken) (2012) 1.06
Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res (2007) 1.04
Echocardiographic alterations in systemic sclerosis: a longitudinal study. Semin Arthritis Rheum (2005) 1.04
Increasing the source/sink ratio in Vitis vinifera (cv Sangiovese) induces extensive transcriptome reprogramming and modifies berry ripening. BMC Genomics (2011) 1.03
Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol (2008) 1.00
Type-1 response in peripheral CD4+ and CD8+ T cells from patients with Hashimoto's thyroiditis. Eur J Endocrinol (2003) 0.97
CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmun Rev (2005) 0.97
Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev (2011) 0.95
Multiprofessional and intrahospital experience for diagnosis and treatment of pulmonary arterial hypertension. Monaldi Arch Chest Dis (2012) 0.95
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol (2009) 0.94
Prevalence of hepatitis C serum antibody in autoimmune diseases. J Autoimmun (2009) 0.94
The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis (2007) 0.94
Osteoclastogenesis and arthritis. Clin Exp Med (2010) 0.93
The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol (2004) 0.92
Ultrasonographic features of the hand and wrist in systemic sclerosis. Rheumatology (Oxford) (2009) 0.90
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res (2011) 0.90
Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol (2009) 0.90
The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. Ann Rheum Dis (2013) 0.90
Successful neridronate therapy in transient osteoporosis of the hip. Clin Rheumatol (2004) 0.89
The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells. Immunol Res (2011) 0.89
Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol (2014) 0.88
High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol (2006) 0.87
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther (2014) 0.87
Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol (2012) 0.87
Bone effects of biologic drugs in rheumatoid arthritis. Clin Dev Immunol (2013) 0.86
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J Immunol (2007) 0.86
Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and/or capillaroscopic positivity. Arthritis Care Res (Hoboken) (2014) 0.85
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Blood Cells Mol Dis (2008) 0.85
Mast cells in rheumatoid arthritis. Clin Rheumatol (2006) 0.85
Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology (2007) 0.85
RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects. J Rheumatol (2013) 0.85
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunol Lett (2005) 0.84
Prevalence of anti-Toxoplasma antibodies in patients with autoimmune diseases. J Autoimmun (2012) 0.84
Systemic effects of Wnt signaling. J Cell Physiol (2013) 0.84
Macrophages and angiogenesis in rheumatic diseases. Vasc Cell (2013) 0.84
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. J Rheumatol (2010) 0.83
CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases. Ann N Y Acad Sci (2005) 0.83
Expression of vascular endothelial growth factor in normal, osteoarthritic and osteoporotic osteoblasts. Clin Exp Med (2011) 0.83
Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. Clin Exp Rheumatol (2013) 0.83
Cell-free DNA in the plasma of patients with systemic sclerosis. Clin Rheumatol (2009) 0.82
The role of infections in the immunopathogensis of systemic sclerosis--evidence from serological studies. Ann N Y Acad Sci (2009) 0.81
In vitro and in vivo angiogenic activity of osteoarthritic and osteoporotic osteoblasts is modulated by VEGF and vitamin D3 treatment. Regul Pept (2013) 0.81
Nailfold capillaroscopic findings in systemic sclerosis related lung fibrosis and in idiopathic lung fibrosis. Joint Bone Spine (2010) 0.81
Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clin Exp Med (2013) 0.81
Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement. Arthritis Res Ther (2012) 0.81
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. Arthritis Res Ther (2013) 0.81
Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Clin Rheumatol (2004) 0.80
TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new? Clin Exp Med (2012) 0.80
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Ann Rheum Dis (2011) 0.80
Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. Arthritis Rheum (2011) 0.80
Apolipoprotein A-I-dependent cholesterol esterification in patients with rheumatoid arthritis. Life Sci (2005) 0.79
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. Health Qual Life Outcomes (2013) 0.79
Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? Rheumatology (Oxford) (2010) 0.79
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatol Int (2003) 0.79
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. Arthritis Rheum (2011) 0.79
The origin of tendon friction rubs in patients with systemic sclerosis: a sonographic explanation. Arthritis Rheum (2011) 0.79
Two cases of distal extremity swelling with pitting oedema in psoriatic arthritis: the different pathological mechanisms. Rheumatol Int (2009) 0.79
The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). Clin Immunol (2010) 0.79
Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol (2006) 0.79